APA (7th ed.) Citation

L, M., AC, V., M, H. R., HE, O., M, E., H, P., . . . B, E. (2026). Discovery of BE2012, a First-in-Class REV-ERBα/β Antagonist with Favorable Selectivity and Pharmacokinetics, and In Vivo Efficacy in Inducing Key Myogenic Factors for Muscle Repair upon Acute Muscle Injury. Journal of medicinal chemistry, 69(1), 439. https://doi.org/10.1021/acs.jmedchem.5c02749

Chicago Style (17th ed.) Citation

L, Maram, et al. "Discovery of BE2012, a First-in-Class REV-ERBα/β Antagonist with Favorable Selectivity and Pharmacokinetics, and In Vivo Efficacy in Inducing Key Myogenic Factors for Muscle Repair upon Acute Muscle Injury." Journal of Medicinal Chemistry 69, no. 1 (2026): 439. https://doi.org/10.1021/acs.jmedchem.5c02749.

MLA (9th ed.) Citation

L, Maram, et al. "Discovery of BE2012, a First-in-Class REV-ERBα/β Antagonist with Favorable Selectivity and Pharmacokinetics, and In Vivo Efficacy in Inducing Key Myogenic Factors for Muscle Repair upon Acute Muscle Injury." Journal of Medicinal Chemistry, vol. 69, no. 1, 2026, p. 439, https://doi.org/10.1021/acs.jmedchem.5c02749.